Verdad Capital's research shows biotech stocks heavily owned by multiple specialist funds significantly outperform those with none. This "consensus" among experts acts as a powerful quality screen in a sector where traditional financial metrics are useless, as stocks with zero specialist ownership generate near-zero returns.

The XBI is at post-pandemic highs, but this isn't a true reflection of the entire sector. Its methodology shifted from an equal-weight index to one favoring larger, liquid companies. Recent M&A of these larger companies has disproportionately driven the index up, masking the performance of smaller biotechs.

The current public market isn't an indiscriminate bull run. It rewards strong data and punishes failure, creating an environment where deep-domain specialty investors, who can discern true value, thrive over generalists.

While broad biotech indices performed poorly, the past two years were manageable and even ideal for investors who were highly selective. The downturn created an environment for skilled stock pickers to identify high-quality companies that could withstand market pressures, proving that sector-wide performance is not the whole story.

Despite biotech comprising a significant portion of benchmarks, generalist managers consistently remain severely underweight. They perceive this as risk-averse, but it actually exposes their funds to massive tracking error and unintended risks by forcing them to be overweight in other healthcare sub-sectors.

Despite the biotech index (XBI) appearing relatively stable, many long-short funds are suffering. This is due to a "degrossing effect" and the underperformance of smaller-cap names within the index. The sector, once seen as impervious to rising interest rates, may now be feeling the pressure.

A closer look at biotech ETFs reveals a bifurcated market recovery. The large-cap weighted IBB is back to its late 2021 peak, but the small-cap focused XBI still lags significantly. This shows that investor capital flowing back into the sector is not lifting all boats equally.

Even with a strong IPO window, many biotech investors aren't seeing universal gains. The market is rewarding specific, often non-obvious takeouts and catalyst-driven events, favoring deep diligence over passive investing, making it an 'inefficient' market.

In an scientifically inscrutable sector, the percentage of a company owned by dedicated biotech funds serves as a reliable proxy for quality. A complete lack of specialist ownership is a major red flag, suggesting the company is likely marketed to uninformed investors and may have poor science.